A5001874320- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- Cancer Research and Treatments
- Tuberculosis Research and Epidemiology
- Cancer Treatment and Pharmacology
- Mycobacterium research and diagnosis
- Cytomegalovirus and herpesvirus research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Immunocore (United Kingdom)
2016-2023
Cardiff University
2012-2018
Summary Fluorochrome-conjugated peptide–major histocompatibility complex (pMHC) multimers are widely used for flow cytometric visualization of antigen-specific T cells. The most common multimers, streptavidin–biotin-based ‘tetramers’, can be manufactured readily in the laboratory. Unfortunately, there large differences between threshold cell receptor (TCR) affinity required to capture pMHC tetramers from solution and that which is activation. This disparity means sometimes fail stain cells...
Tumor-associated peptide–human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface–expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that incorporate an anti-CD3 effector function are being developed to redirect T cells against these using 2 different approaches. The first achieves pHLA recognition via affinity-enhanced versions natural TCRs (e.g., immune-mobilizing monoclonal receptors [ImmTAC]...
Mucosal-associated invariant T (MAIT) cells use canonical semi-invariant cell receptors (TCR) to recognize microbial riboflavin precursors displayed by the antigen-presenting molecule MR1. The extent of MAIT TCR crossreactivity toward physiological, microbially unrelated antigens remains underexplored. We describe TCRs endowed with MR1-dependent reactivity tumor and healthy in absence metabolites. bearing crossreactive self are rare but commonly found within donors display T-helper-like...
Basic parameters of the naive antigen (Ag)‐specific T‐cell repertoire in humans remain poorly defined. Systematic characterization this ‘ground state’ immunity comparison with memory will allow a better understanding clonal selection during immune challenge. Here, we used high‐definition cell isolation from umbilical cord blood samples to establish baseline frequency, phenotype and receptor (TCR) CD8 + precursor populations specific for range viral self‐derived Ags. Across board, these were...
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through generation of highly stable antigenic "mimics" using subunits that do not exist natural world. We developed a platform based on D–amino acid combinatorial chemistry used this reverse engineer fully artificial CD8+ cell agonist mirrored immunogenicity...
OPINION article Front. Immunol., 05 June 2013Sec. T Cell Biology Volume 4 - 2013 | https://doi.org/10.3389/fimmu.2013.00133
e14579 Background: TROCEPT is a novel tumor-selective replicating, oncolytic adenovirus type 5 (Ad5) rationally engineered to remove all natural tissue tropisms. This engineering addresses the main limitation of other viral therapies which infect normal tissues and are rapidly removed by liver therefore limited local delivery. has been further specifically bind αvβ6 integrin expressed at high frequency in majority epithelial cancers, so that following intravenous delivery virus targets tumor...
Abstract For years cancer therapies were mainly concentrated around surgery, chemotherapy and radiotherapy. Recently, a new domain has emerged. Immunotherapies aim to exploit, enhance optimise the patient's immune system be more potent at eradicating tumours. T-cell immunotherapies, however, often encounter challenges with low cell surface expression of tumour-associated-antigens (TAAs), down-regulation class I MHC molecules avidity for TAAs, all contributing tumour escape. To address these...
Abstract TCRs expressed at the CD8+ T-cell surface interact with short peptide fragments bound to MHC class I molecules (pMHCI). The TCR/pMHCI interaction is pivotal in all aspects of immunity. However, rules that govern outcome engagement are not entirely understood, and this a major barrier understanding requirements for both effective immunity vaccination. Using large combinatorial arrays, each containing between twenty billion forty quadtrillion distinct peptides, we have discovered an...
<h3>Background</h3> TROCEPT is a novel tumor-selective oncolytic adenovirus type 5 engineered to remove all natural tissue tropisms. This engineering addresses the main limitation of other viral therapies which infect normal tissues and are rapidly removed by liver, thereby limiting tumour bioavailability. has been further specifically bind αvβ6 integrin expressed at high frequency in majority epithelial cell derived cancers. In addition, platform can encode transgenes enables...
<h3>Background</h3> Immune checkpoint inhibitors (ICIs) have revolutionized immunotherapy, but their efficacy is limited to certain cancers, and response rates are largely dependent on the ability of patients T cells recognize activate against tumor antigens. Additionally, systemic delivery can lead dose limiting toxicity.<sup>1</sup> TROCEPT a novel tumor-selective technology, based type 5 adenovirus, engineered not enter normal human tissues. The removal tissues tropisms addresses main...